Oncolytics' Pelareorep Shows Enhanced Anti-Tumor Activity in Preclinical RAS-Targeted Combo
ONCY has more than doubled off its 52-week low of $0.326 on elevated volume (2.7× avg).
Summary
Oncolytics Biotech reported positive preclinical data for its lead drug, pelareorep, showing enhanced anti-tumor activity when combined with RAS inhibitor modalities. This expands the potential therapeutic applications for pelareorep, particularly in RAS-mutated cancers, building on previous positive clinical data for the drug. While preclinical, this development supports the drug's mechanism of action and future market potential, which is important for a company with an active $75 million ATM offering and a 'going concern' warning. The full dataset from these initial preclinical studies is anticipated in fall or winter 2026.
At the time of this announcement, ONCY was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.1M. The 52-week trading range was $0.33 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.